CliffBio
small molecule

METOPROLOL SUCCINATE

METOPROLOL SUCCINATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameMETOPROLOL SUCCINATE
Active ingredientMETOPROLOL SUCCINATE
StrengthEQ 200MG TARTRATE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2018
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

METOPROLOL SUCCINATE patent cliff — loss of exclusivity — | CliffBio